Melissa L Johnson

Melissa L Johnson

UNVERIFIED PROFILE

Are you Melissa L Johnson?   Register this Author

Register author
Melissa L Johnson

Melissa L Johnson

Publications by authors named "Melissa L Johnson"

Are you Melissa L Johnson?   Register this Author

33Publications

1361Reads

41Profile Views

Team-Based Care and Patient Satisfaction in the Hospital Setting: A Systematic Review.

J Patient Cent Res Rev 2019 29;6(2):158-171. Epub 2019 Apr 29.

Center for Advancing Interprofessional Practice, Education and Research, Edson College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17294/2330-0698.1695DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676761PMC
April 2019

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

N Engl J Med 2018 12 25;379(23):2220-2229. Epub 2018 Sep 25.

From Vanderbilt University Medical Center (L. Horn) and Sarah Cannon Research Institute-Tennessee Oncology (M.L.J.), Nashville; Mayo Clinic, Rochester, MN (A.S.M.); Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy, Otwock (A. Szczęsna), and Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie w Warszawie, Warsaw (M.K.) - both in Poland; Thomayerova Nemocnice, Pneumologická Klinika 1.LF UK, Prague, Czech Republic (L. Havel); the Department of Respiratory and Critical Care Medicine (M.J.H.) and the 2nd Department of Respiratory and Critical Care Medicine (F.H.), Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology-Sozialmedizinisches Zentrum Baumgartner Höhe, Otto-Wagner-Spital, Vienna; Semmelweis Egyetem ÁOK, Pulmonológiai Klinika, Budapest, Hungary (G.L.); the Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo (M.N.); LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany (M.R.); State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong (T.M.), and F. Hoffmann-La Roche, Shanghai (J.L.) - both in China; Genentech, South San Francisco, CA (S.L., D.S.S., B.D., A.L.-C., F.K., W.L., A. Sandler); and Georgetown University, Washington DC (S.V.L.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1809064
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1809064DOI Listing
December 2018

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.

N Engl J Med 2018 07 4;379(4):341-351. Epub 2018 Jun 4.

From the Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston (M.R.M.), and South Texas Accelerated Research Therapeutics (START), San Antonio (K.P.P.) - both in Texas; the Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC (D.R., A.A.T.), the Department of Medical Oncology, Royal North Shore Hospital, St. Leonards, VIC (A.G.), the Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA (A.M.L.), and Royal Brisbane and Women's Hospital and University of Queensland, Brisbane (B.G.M.H.) - all in Australia; the Department of Dermatology, Brigham and Women's Hospital (C.D.S.), the Department of Dermatology, Harvard Medical School (C.D.S.), and the Department of Medical Oncology, Dana-Farber Cancer Institute (G.R.) - all in Boston; Schleswig-Holstein University Hospital, Kiel (A.H.), and University Hospital Essen, Essen and German Cancer Consortium, Essen (D.S.) - both in Germany; University of Colorado Denver, School of Medicine, Aurora (K.D.L.); the Departments of Head and Neck-Endocrine Oncology (C.H.C.) and Cutaneous Oncology (N.I.K.), H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; the Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis (L.H.-A.); the Department of Dermatology, Stanford University School of Medicine, Redwood City (A.L.S.C.), and the Division of Dermatology, City of Hope, Duarte (B.M.) - both in California; the Department of Medicine, Head and Neck Medical Oncology, Memorial Sloan Kettering Cancer Center, New York (L.A.D.), and Regeneron Pharmaceuticals, Tarrytown (F.S., M.M., K.M., G.D.Y., I.L., M.G.F.) - both in New York; Regeneron Pharmaceuticals, Basking Ridge, NJ (B.G., S.L., J.L., J.B., E.S.); University of Arizona Cancer Center, Tucson (H.M.B.), and Banner MD Anderson Cancer (J.H.) and the Department of Medical Oncology, Banner MD Anderson Cancer Center (J.N.), Gilbert - all in Arizona; Medical Oncology Department, Vall D'Hebron University Hospital (I.B.), and Institut Català D'Oncologia, Oncobell Program (IDIBELL), L'Hospitalet de Llobregat (M.G.-M.), Barcelona, and START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid (V.M.) - all in Spain; Sarah Cannon Research Institute, Nashville (M.L.J.); and the Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta (T.K.O.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1805131
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1805131DOI Listing
July 2018

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

J Clin Oncol 2018 04 26;36(12):1199-1206. Epub 2018 Jan 26.

Jessica J. Lin, Satoshi Yoda, Beow Y. Yeap, Ibiayi Dagogo-Jack, Nicholas A. Jessop, Ginger Y. Jiang, Long P. Le, Aaron N. Hata, Justin F. Gainor, Anthony J. Iafrate, and Alice T. Shaw, Massachusetts General Hospital, Boston; Alexa B. Schrock, Kyle Gowen, Philip J. Stephens, Jeffrey S. Ross, Siraj M. Ali, and Vincent A. Miller, Foundation Medicine, Cambridge, MA; Viola W. Zhu and Sai-Hong Ignatius Ou, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA; Melissa L. Johnson, Sarah Cannon Research Institute; and Christine M. Lovly, Vanderbilt-Ingram Cancer Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.2294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903999PMC
April 2018

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

J Clin Oncol 2017 Aug 13;35(24):2781-2789. Epub 2017 Jun 13.

Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne; Martin Früh, Kantonsspital St Gallen, St Gallen, Switzerland; Scott Gettinger, Yale Cancer Center, New Haven, CT; Melissa L. Johnson, Sarah Cannon Research Institute, Nashville, TN; Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA; Marina C. Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Daniel Christoph, Universitätsklinikum Essen, and the Ruhrlandklinik, Universität Duisburg-Essen, Essen; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany; Chee Keong Toh, National Cancer Centre, Singapore, Singapore; Naiyer A. Rizvi and Jamie E. Chaft, Memorial Sloan Kettering Cancer Center; Jamie E. Chaft, Weill Cornell Medical College, New York, NY; Enric Carcereny Costa, Catalan Institute of Oncology Badalona, Badalona; Luis Paz-Ares, Hospital Universitario Doce de Octubre & IIS i+12, CNIO, Ciberonc and Universidad Complutense, Madrid; Enriqueta Felip, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Jyoti D. Patel, University of Chicago, Chicago, IL; Laura Q.M. Chow, University of Washington, Seattle, WA; Marianna Koczywas, City of Hope, Duarte; Zhengrong Li, Jiaheng Qiu, Marcin Kowanetz, Simonetta Mocci, Geetha Shankar, and Alan Sandler, Genentech, South San Francisco, CA; Cheryl Ho, Vancouver Centre, BC Cancer Agency, Vancouver, British Columbia; Jeffrey Rothenstein, R.S. McLaughlin Durham Regional Cancer Centre, Oshawa; Frances A. Shepherd, Princess Margaret Cancer Centre/University Health Network and University of Toronto, Toronto, Ontario, Canada; Michel van den Heuvel, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; and Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.9476DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562171PMC
August 2017

FGFR3-TACC3: A novel gene fusion in cervical cancer.

Gynecol Oncol Rep 2015 Aug 18;13:53-6. Epub 2015 Jun 18.

Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University 645 N Michigan Ave Suite 1006 Chicago, IL, 60611, Unites States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gore.2015.06.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563584PMC
August 2015

Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline.

J Clin Oncol 2015 Jun 5;33(18):2100-5. Epub 2015 May 5.

Andrea Bezjak, Princess Margaret Cancer Center, Toronto, Ontario, Canada; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Gregg Franklin, New Mexico Cancer Center, Albuquerque, NM; Giuseppe Giaccone, Lombardi Cancer Center, Washington, DC; Ramaswamy Govindan, Washington University, St Louis, MO; Melissa L. Johnson, Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; Andreas Rimner, Memorial Sloan Kettering Cancer Center; Bryan J. Schneider, Weill Cornell Medical College, New York, NY; John Strawn, Patient Representative, Houston, TX; and Christopher G. Azzoli, Massachusetts General, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2014.59.2360
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.59.2360DOI Listing
June 2015

Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

J Clin Oncol 2015 May 13;33(15):1666-73. Epub 2015 Apr 13.

Melissa L. Johnson, Jyoti D. Patel, Eric M. Hart, Bing Bing Weitner, and Alfred W. Rademaker, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; and Helena A. Yu, Mark G. Kris, and Gregory J. Riely, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/04/13/JCO.2014.59
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.59.7328
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.59.7328DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881377PMC
May 2015

Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer.

Oncologist 2015 Mar 6;20(3):299-306. Epub 2015 Feb 6.

Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, Virginia, USA; Sarah Cannon Research Institute, Nashville, Tennessee, USA

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2014-0212DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350796PMC
March 2015

The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria.

Cancer 2014 Dec 25;120(24):3853-8. Epub 2014 Aug 25.

Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28956DOI Listing
December 2014

Reversible nyctalopia and retinopathy in a patient with metastatic cancer treated with anti-heat shock protein 90 therapy.

JAMA Ophthalmol 2014 Jul;132(7):899-901

Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaophthalmol.2014.409DOI Listing
July 2014

Chemotherapy and targeted therapeutics as maintenance of response in advanced non-small cell lung cancer.

Semin Oncol 2014 Feb 12;41(1):93-100. Epub 2013 Dec 12.

Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2013.12.007DOI Listing
February 2014

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.

Cancer 2013 Jan 18;119(2):356-62. Epub 2012 Jul 18.

Feinberg School of Medicine, Northwestern University, The Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.27730DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3966555PMC
January 2013

Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers.

J Thorac Oncol 2013 Jan;8(1):123-5

Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e31827914eaDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534987PMC
January 2013

Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.

Cancer 2012 Dec 17;118(23):5840-7. Epub 2012 May 17.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.27637DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424296PMC
December 2012

A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.

J Thorac Oncol 2011 Aug;6(8):1435-7

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York City, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e318223c099DOI Listing
August 2011

Emerging targeted therapies for breast cancer.

Oncology (Williston Park) 2005 Apr;19(5):611-8

Joan and Sanford I. Weill Medical College, Cornell University, New York, New York, USA.

View Article

Download full-text PDF

Source
April 2005